High Mark Wealth Management LLC Krystal Biotech, Inc. Transaction History

High Mark Wealth Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 20, 2022	SELL	$39.81 - $88.24 $7,603 - $16,853	-191 Reduced 1.1%	17,185 $1.2 Million
Q3 2021 Nov 01, 2021	BUY	$52.01 - $71.77 $5,148 - $7,105	99 Added 0.57%	17,376 $907,000
Q2 2021 Aug 02, 2021	BUY	$62.14 - $81.82 $5,281 - $6,954	85 Added 0.49%	17,277 $1.18 Million
Q1 2021 Apr 22, 2021	SELL	$59.42 - $85.46 $23,411 - $33,671	-394 Reduced 2.24%	17,192 $1.32 Million
Q4 2020 Jan 27, 2021	SELL	$40.64 - $61.38 $53,157 - $80,285	-1,308 Reduced 6.92%	17,586 $1.06 Million
Q3 2020 Oct 26, 2020	BUY	$37.76 - $48.49 $57,584 - $73,947	1,525 Added 8.78%	18,894 $813,000
Q2 2020 Jul 22, 2020	BUY	$37.03 - $60.0 $643,174 - $1.04 Million	17,369 New	17,369 $719,000

306

24.2M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.97B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of High Mark Wealth Management LLC, based on Form 13F filings with the SEC.

Stay updated on High Mark Wealth Management LLC with notifications on news.